BIO-TECHNE Corp
TECH- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0000842023
No open-market purchases or sales by BIO-TECHNE Corp insiders were filed in the last 90 days; 596 institutions reported holding it in 13F filings for Q2 2026, worth $12.3B in total; 3 superinvestors hold it, including Maverick Capital and Weitz Investment Management.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by BIO-TECHNE Corp insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 0 filings
- Open-market sells
- 0 filings
- Insiders trading
- 0
- Net value
- $0
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for BIO-TECHNE Corp, current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Baumgartner Robert V | Director | 56,884 | Sep 24, 2026 | 2 |
| Bohnen Shane | SVP - General Counsel | 10,360 | Aug 19, 2026 | 5 |
| Kelderman Kim | Chief Executive Officer | 82,762 | Aug 19, 2026 | 7 |
| Hippel James | CFO | 170,183 | Aug 19, 2026 | 6 |
| Herr Amy E. | Director | 576Indirect | Aug 19, 2026 | 6 |
| Geist William | PRESIDENT, PROTEIN SCIENCES | 24,943 | Aug 19, 2026 | 3 |
| Crouse Steven C. | President - Diag & Spatial Bi | 10,237 | Aug 19, 2026 | 5 |
| McManus Matthew | President - Diag & Spatial Bio | 7,691 | Feb 3, 2026 | 1 |
| Higgins John L | Director | 66,876 | Nov 3, 2025 | 1 |
| Keegan Joseph D | Director | 15,411 | Nov 3, 2025 | 1 |
| Bushman Julie L | Director | 8,775 | Nov 3, 2025 | 1 |
| Vessey Rupert | Director | 10,987 | Nov 3, 2025 | 1 |
| Seth Alpna | Director | 15,411 | Nov 3, 2025 | 1 |
| Klimovsky Judith V | Director | 3,782 | Nov 3, 2025 | 1 |
| Nusse Roeland | Director | 44,559 | Aug 27, 2025 | 0 |
| Steer Randolph C | Director | 24,201 | Oct 30, 2023 | 0 |
| Kummeth Charles R. | Chief Executive Officer | 1,278,269 | Aug 17, 2023 | 0 |
| Furlow Brenda S. | SVP - GENERAL COUNSEL | 26,092 | Dec 9, 2022 | 0 |
| Eansor Norman David | President-Protein Sciences | 2,117 | Nov 16, 2021 | 0 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| May 12, 2026 (view filing) | May 8 | 4 days | Herr Amy E.Director | SSale | −6.64K | $48.28 | −$320.4K | −97.1%200 after | |
| Feb 19, 2026 (view filing) | Feb 17 | 2 days | Herr Amy E.Director | SSale | −1.98K | $59.11 | −$116.8K | −90.8%200 after | |
| Aug 27, 2025 (view filing) | Aug 25 | 2 days | Nusse RoelandDirector | SSale | −17.0K | $56.36 | −$960.4K | −27.7%44.6K after | |
| Aug 27, 2025 (view filing) | Aug 25 | 2 days | Baumgartner Robert VDirector | SSale | −17.0K | $56.21 | −$957.8K | −27.5%44.9K after | |
| Jun 11, 2025 (view filing) | Jun 9 | 2 days | Herr Amy E.Director | SSale | −1.28K | $49.77 | −$63.7K | −39.3%1.98K after | |
| Feb 18, 2025 (view filing) | Feb 14 | 4 days | Herr Amy E.Director | SSale | −1.86K | $65.96 | −$122.7K | −48.5%1.98K after | |
| Jan 29, 2025 (view filing) | Jan 27 | 2 days | Kelderman KimChief Executive Officer | SSale | −13.4K | $77.28 | −$1.03M | −25.6%39.0K after | 2 lots |
| Aug 12, 2024 (view filing) | Aug 8 | 4 days | Baumgartner Robert VDirector | SSale | −16.0K | $72.10 | −$1.15M | −26.9%43.4K after | |
| May 16, 2024 (view filing) | May 14 | 2 days | Higgins John LDirector | SSale | −4.00K | $83.84 | −$335.4K | −9.9%36.6K after | |
| Mar 11, 2024 (view filing) | Mar 7 | 4 days | Nusse RoelandDirector | SSale | −10.4K | $76.98 | −$800.6K | −19.4%43.1K after | |
| Sep 1, 2023 (view filing) | Aug 30 | 2 days | Nusse RoelandDirector | SSale | −8.94K | $80.32 | −$718.0K | −14.7%51.9K after | |
| Jul 25, 2023 (view filing) | Jul 21 | 4 days | Kummeth Charles R.Chief Executive Officer | SSale | −80.0K | $88.36 | −$7.07M | −6.0%1.26M after | 10b5-1 |
| Jun 9, 2023 (view filing) | Jun 7 | 2 days | Kummeth Charles R.Chief Executive Officer | SSale | −322 | $83.00 | −$26.7K | 0.0%1.11M after | |
| Dec 9, 2022 (view filing) | Dec 7-8 | 2 days | Furlow Brenda S.SVP - GENERAL COUNSEL | SSale | −8.25K | $82.11 | −$677.4K | −24.0%26.1K after | 2 lots |
| Aug 12, 2022 (view filing) | Aug 10-11 | 2 days | Higgins John LDirector | SSale | −2.50K | $378.80 | −$948.5K | −31.3%5.50K after | 5 lots |
| Jun 9, 2022 (view filing) | Jun 7-8 | 2 days | Higgins John LDirector | SSale | −1.60K | $364.98 | −$584.0K | −25.8%4.61K after | 2 lots |
| Jun 9, 2022 (view filing) | Jun 7 | 2 days | Kummeth Charles R.CHIEF EXECUTIVE OFFICER | SSale | −5.10K | $365.00 | −$1.86M | −2.5%198.3K after | |
| May 11, 2022 (view filing) | May 10 | 1 day | Baumgartner Robert VDirector | PPurchase | +300 | $352.55 | +$105.8K | +3.1%10.1K after | |
| Nov 23, 2021 (view filing) | Nov 19 | 4 days | Kelderman KimPres. Diagnostics & Genom | SSale | −500 | $505.38 | −$252.7K | −100.0%0 after | 2 lots |
| Nov 16, 2021 (view filing) | Nov 12 | 4 days | Eansor Norman DavidPresident-Protein Sciences | SSale | −27.2K | $504.00 | −$13.7M | −95.4%1.32K after | 10 lots |
| Nov 3, 2021 (view filing) | Nov 1-2 | 2 days | Hippel JamesChief Financial Officer | SSale | −9.02K | $526.49 | −$4.75M | −45.6%10.8K after | 5 lots |
| Nov 1, 2021 (view filing) | Oct 28-29 | 4 days | Hippel JamesChief Financial Officer | SSale | −762 | $525.22 | −$400.2K | −6.6%10.8K after | 2 lots |
| Sep 24, 2021 (view filing) | Sep 22 | 2 days | Kelderman KimPres. Diagnostics & Genom | SSale | −822 | $529.04 | −$434.9K | −100.0%0 after | |
| Sep 9, 2021 (view filing) | Sep 7 | 2 days | Steer Randolph CDirector | SSale | −8.00K | $509.98 | −$4.08M | −61.0%5.11K after | 3 lots |
| Sep 7, 2021 (view filing) | Sep 2 | 5 days | Hippel JamesChief Financial Officer | SSale | −10.0K | $507.22 | −$5.07M | −48.0%10.9K after | 2 lots |
| Sep 7, 2021 (view filing) | Sep 2 | 5 days | Furlow Brenda S.SVP - General Counsel | SSale | −6.87K | $509.93 | −$3.50M | −47.4%7.62K after | 2 lots |
| Sep 2, 2021 (view filing) | Aug 31 | 2 days | Eansor Norman DavidPresident-Protein Sciences | SSale | −1.54K | $503.07 | −$773.7K | −53.9%1.32K after | |
| Sep 2, 2021 (view filing) | Aug 31 | 2 days | Furlow Brenda S.SVP - General Counsel | SSale | −5.00K | $505.66 | −$2.53M | −39.6%7.62K after | 3 lots |
| Aug 25, 2021 (view filing) | Aug 23 | 2 days | Nusse RoelandDirector | SSale | −4.00K | $481.52 | −$1.93M | −37.2%6.76K after | |
| Aug 25, 2021 (view filing) | Aug 23 | 2 days | Baumgartner Robert VDirector | SSale | −4.00K | $485.54 | −$1.94M | −29.4%9.61K after | 6 lots |
| Aug 23, 2021 (view filing) | Aug 19 | 4 days | Furlow Brenda S.SVP - General Counsel | SSale | −3.54K | $473.95 | −$1.68M | −31.7%7.62K after | 3 lots |
| Aug 10, 2021 (view filing) | Aug 9 | 1 day | Hippel JamesChief Financial Officer | SSale | −10.0K | $478.90 | −$4.79M | −48.0%10.9K after | 8 lots |
| Jul 14, 2021 (view filing) | Jul 12 | 2 days | Hippel JamesChief Financial Officer | SSale | −10.0K | $456.67 | −$4.57M | −52.3%9.14K after | 13 lots |